AI for life sciences research
Ask one question across scientific and medical literature, clinical evidence, and global regulatory sources.
Sources Arca searches and cites
Medical
Cochrane Library
World Health Organization
Scientific
PubMed
bioRxiv
Springer Nature
Regulatory
U.S. FDA
European Medicines Agency
ICH
Use cases by team
Medical Affairs
Turn literature, clinical guidelines, and competitor evidence into cited answers for scientific exchange and evidence planning.
- Medical information
- Evidence planning
- Congress prep
Regulatory Affairs
Trace agency guidance, approvals, labels, and precedent to support submissions and regulatory strategy.
- Precedent research
- Label comparisons
- Submission support
Pharmacovigilance
Investigate adverse-event patterns, safety signals, label changes, and supporting literature across products.
- Signal validation
- Case context
- Safety surveillance
R&D
Map mechanisms, targets, trials, endpoints, and competitive programs to guide portfolio and development decisions.
- Target research
- Trial landscapes
- Competitive intelligence
Example questions
Questions that take a specialist an afternoon across four databases, answered with every claim linked to the document it came from.
Regulatory affairs
- Which 510(k)s cite this device as a predicate, and what did FDA say about substantial equivalence?
- Has FDA ever accepted this surrogate endpoint in our indication, and in which approvals?
- What deficiencies has this review division raised in Complete Response Letters for similar products?
- How does our proposed labelling differ from the approved labelling of the reference product?
Medical affairs
- What does the published evidence say about this off-label use, and how strong is it?
- Which guidelines cite this trial, and what did they conclude from it?
- What has been presented on this mechanism at congress in the last two years?
Pharmacovigilance
- Are adverse event reports for this class trending, and against what exposure?
- Which label changes followed the safety signal we are investigating?
- What does the literature say about this event as a class effect rather than a product effect?
Research and development
- Which trials are recruiting against this target, with what endpoints?
- What has failed in this indication, and at which phase did it fail?
Try the underlying data first
The same FDA sources, searchable without an account. No signup, and nothing you type is stored.
- eCTD viewerOpen an eCTD submission ZIP or folder, navigate its modules and sequences, and preview documents in your browser. Package files stay on your device.
- Clinical trial drug trackerExplore the latest drug and biologic trial updates by phase, status, sponsor and condition, with links to ClinicalTrials.gov.
- FDA 510(k) searchSearch every clearance FDA has issued since 1976 by device, applicant, K number or product code.
- FDA Complete Response Letter searchSearch every CRL FDA has published, including the full letter text, with FDA's own deficiency headings on each result.
- FDA warning letter searchSearch FDA's published warning letters by company, issuing office, year and subject, and see which ones FDA has closed out.
- FDA OPDP untitled letters searchSearch FDA's untitled and promotion warning letters by company, product, format and what FDA cited, with close-out dates and a link to every letter.
- Pharma company FDA recordsApprovals, warning letters, complete response letters, OPDP letters, recalls and inspection outcomes for the largest drug companies, counted from FDA's public records.
- FDA debarment list searchSearch FDA's drug debarment lists by name, date, term or Federal Register citation, with the basis for each order and a link to the notice.
- FDA AI-enabled medical devices listSearch all devices on FDA's AI-enabled medical device list by company, year, panel, pathway and product code, with a link to FDA's own record for each.
- Orange Book patent and exclusivity expirySee which drugs reach the end of their last listed Orange Book patent or exclusivity, by year and sponsor, with the full table and a CSV.
- FDA inspection searchSearch FDA inspection outcomes by firm, classification, year and country, with OAI results flagged and the CFR sections cited on Form 483s.
- FDA recall announcementsEvery company recall announcement FDA has posted since 2017, for drugs, devices, food, supplements and pet food, with the reason and the press release.
- FDA recall searchSearch drug and device recalls by the reason FDA recorded, with Class I flagged on every result.
- FDA MAUDE database searchSearch medical device adverse event reports by device, manufacturer, product code, event type, date or report number, and read the narratives.
- FDA product code lookupLook up any FDA product code, device name or regulation number and see its class, regulation and review panel, plus the flags that point to Part 820 requirements under the QMSR, with the rule cited.
- GUDID device lookupPaste the UDI from a device label and see what it is, who makes it, and the 510(k) that cleared it.
- PRISMA flow diagram generatorEnter your record counts and get a PRISMA 2020 flow diagram that adds up, ready to download as PNG or SVG.
- Priority review voucher sales and FDA awardsEvery priority review voucher sale with a disclosed price, buyer and source filing, plus the rare pediatric disease and countermeasure vouchers FDA has announced.
- Medicare drug price negotiation trackerEvery drug CMS selected for Medicare price negotiation, by round, with manufacturers, negotiated prices against list prices, effective dates, Medicare spending and the calendar of next steps.
- FDA drug shortagesEvery drug on FDA's shortage list, grouped by drug: what is short now, what was added or resolved in the last 30 days, why, and which companies make it.
- Biotech cash runwayCash and short-term investments over yearly operating cash burn for every US-listed pharma and biotech company that files 10-Qs, from SEC XBRL data.
- FDA compliance programsEvery FDA compliance program for drugs, devices, biologics and clinical research, with its number, what it covers and FDA's PDF.
- 21 CFR lookupEvery section of 21 CFR that FDA investigators cite in inspections: the regulation's text, how often it is cited by year, and the sites cited.
- Health Canada recallsEvery medical device and drug recall Health Canada posts: Type I, II and III, by issue and category, searchable, with device recalls joined to the company that holds the licence.
- Health Canada device licencesEvery active Health Canada medical device licence (Class II to IV): new licences, risk class and the companies that hold them, joined to their FDA records.
- Medicare drug spendingWhat Medicare Part D and Part B spend on each drug, the largest and the fastest-growing, from CMS's spending-by-drug data.
- FDA import refusalsEvery shipment line FDA refused at the US border since 2024, by firm, country, product and charge, from FDA's Import Refusal Report.
- This week at FDAEverything FDA announced in the last 14 days: recall announcements, MedWatch safety alerts, press releases and FDA rules and notices in the Federal Register.
- Why FDA says noEvery published complete response letter as one dot, grouped by whether FDA cited manufacturing, clinical evidence, both or something else.
- FDA inspections mapFDA drug, device and biologic inspections from the last 12 months by site country, shaded by the share FDA classified Official Action Indicated.
- CBER biologicsEvery vaccine, gene and cell therapy, blood product and allergenic licensed by FDA's biologics center, which Drugs@FDA leaves out.
- FTC rules for health companiesThe 16 CFR rules health and life-sciences companies run into: endorsements, fake reviews, health data breaches, subscriptions and eye care, with full text.
- Drug safety communicationsEvery FDA Drug Safety Communication since 2020, with the drugs each one names linked to their FDA records, and which added a boxed warning.
- Orphan drug designationsEvery orphan drug designation FDA has granted since 1983, which reached approval and how long it took, and when each seven-year orphan exclusivity ends.
- EU drug approvalsEvery medicine the European Medicines Agency has authorised, refused or seen withdrawn, with each new active substance's first US approval and the months between them.
- Japan drug approvalsEvery new drug approval Japan's PMDA has listed since 2008, with each new active ingredient's first US approval and the months between them.
- Canada clinical trial authorizationsEvery drug trial Health Canada has authorized since 2013, with its sponsor, investigational products, conditions and status.
- Humanitarian Device ExemptionsEvery Humanitarian Device Exemption FDA has approved since 1997, for devices treating conditions affecting under 8,000 people a year in the US.
- Japan device approvalsEvery new medical device Japan's PMDA has listed since 2007, with FDA's approval date and 510(k) or PMA number where PMDA gives one, and PMDA's review time.
- State AG antitrust cases in health careMultistate antitrust cases state attorneys general have brought against drug makers, hospitals, pharmacies and other health-care companies, from NAAG's case database.
- Health marketing enforcementEvery FDA and FTC letter about how a drug, device or health product is marketed: warning letters citing marketing claims, OPDP drug-ad letters and FTC health letters.
- Medicaid drug spendingWhat state Medicaid programs paid pharmacies for each outpatient drug, with prescriptions, the yearly change and each state's total, from CMS's State Drug Utilization Data.
- Medicare Part D by stateMedicare Part D drug costs in every state, the share of claims that are opioids, antibiotics and antipsychotics, and each state's most distinctive drug.
- Drug price changes (NADAC)What US retail pharmacies pay per unit for about 4,700 prescription drugs, from CMS's weekly NADAC survey, with the change from a year ago.
- NIH grants to companiesEvery NIH award to a for-profit company since fiscal 2020, mostly SBIR and STTR small-business grants, from NIH RePORTER.
- Open Payments by companyWhat every drug and device maker reported paying US doctors, other prescribers and teaching hospitals each year since 2019 under the Sunshine Act, from CMS Open Payments.
- Biotech fundingPrivate fundraising by biotech, pharma and other health-care companies from SEC Form D notices since 2016, current to the week.
- Who was in the trialsFor each new drug FDA approved since 2022, the share of women, people 65 and older, and Black, Hispanic and Asian participants in its trials, from FDA's Drug Trials Snapshots.
- Obesity drug raceEvery obesity and weight-loss drug in company trials since 2018, from ClinicalTrials.gov, with how far each has run and which FDA has approved.
- Regulatory brief for your productDescribe a drug or device in one sentence and get a brief built from public FDA records: comparable approvals, complete response letters, review times, inspection outcomes and enforcement.
Frequently asked questions
- What sources does Arca Research search?
- Regulatory sources including FDA, EMA and ICH, clinical sources including ClinicalTrials.gov and the Cochrane Library, and scientific literature including PubMed, bioRxiv and Springer Nature, across more than 80 sources in total.
- How is this different from asking a general AI model?
- Every claim is cited to the source document it came from, and the sources are the primary record rather than whatever the model absorbed in training. You can open each citation and check it before the answer goes into a filing.
- Can I check the answers?
- Yes. Each statement links to the passage it came from, so checking it takes one click rather than a separate search.
- Is my data used for training?
- No. Arca does not use customer data to train general-purpose AI models. Arca stores research conversations to provide the service. Model-provider processing and retention are separate; see our security page and DPA for details.
- Do I need an account to try it?
- Arca Research asks for an email address. The FDA database tools, covering 510(k) clearances, device identifiers and Complete Response Letters, need no account at all and store nothing you type.
- Which teams use it?
- Regulatory affairs for precedent and label comparisons, medical affairs for evidence and scientific exchange, pharmacovigilance for signal investigation, and R&D for target and competitive research.